Trials / Completed
CompletedNCT01909492
Measurement of Relaxin Peptide in Multiple Sclerosis (MS)
Measurement of Relaxin in the Serum and Cerebrospinal Fluid of Subjects With and Without the Relapsing Form of Multiple Sclerosis
- Status
- Completed
- Phase
- —
- Study type
- Observational
- Enrollment
- 30 (actual)
- Sponsor
- Providence Health & Services · Academic / Other
- Sex
- Female
- Age
- 18 Years – 45 Years
- Healthy volunteers
- Not accepted
Summary
This study will evaluate relaxin (RLX) levels in patients with multiple sclerosis.
Detailed description
The goal of this study is to obtain baseline information on serum and cerebrospinal fluid (CSF) relaxin levels in patients with MS, as well as to further study RXFP-1 receptor binding affinity for RLX in patients with active and clinically stable MS.
Conditions
Interventions
| Type | Name | Description |
|---|---|---|
| PROCEDURE | Blood Draw | Patients will provide a serum sample for research. |
| PROCEDURE | Lumbar Puncture | Patients will have a lumbar puncture to obtain CSF. |
Timeline
- Start date
- 2013-09-20
- Primary completion
- 2023-10-05
- Completion
- 2023-10-05
- First posted
- 2013-07-26
- Last updated
- 2025-06-22
- Results posted
- 2025-06-22
Locations
1 site across 1 country: United States
Source: ClinicalTrials.gov record NCT01909492. Inclusion in this directory is not an endorsement.